Tuesday March 26th 2024



InnoSer, a pioneering leader in pre-clinical research services, is delighted to announce its strategic partnership with CR2O, a full-service clinical CRO specialised in managing complex clinical trials. Through this collaboration, InnoSer and CR2O can offer an integrated drug discovery and development platform that seamlessly progresses high-value clinical candidates from pre-clinical to clinical research and market authorization.

The strategic collaboration between InnoSer and CR2O bridges a critical gap between pre-clinical and clinical development, two areas plagued by high failure rates, escalating costs, and lengthy timelines. By enabling a more integrated and holistic approach to drug development, InnoSer and CR2O empower their clients to increase success rates, enhance efficiency, and reduce the time-to-market of their ground-breaking treatments. This not only facilitates a smoother process between the preclinical to clinical transition but also aligns with InnoSer and CR2O’s commitment to innovation and excellence in bringing new therapies to patients in need.

Through these combined efforts, clients of InnoSer and CR2O will benefit from an integrated service offering, encompassing everything from early-stage drug discovery services to the execution of phase I-IV clinical trials. This synergy allows for a more agile and collaborative research journey, ensuring that every phase is meticulously planned and executed with clinical and regulatory implications in mind. Furthermore, the combined expertise of both organizations will grant researchers access to a broader range of specialized services and optimized strategies for advancing drug candidates. These services include, but are not limited to, toxicology, pharmacology, preclinical program management, CMC advice and management, regulatory strategy and clinical operations.

“In selecting CR2O as our strategic partner, we aim to provide our clients with critical regulatory insights earlier on in their discovery journey by leveraging over a decade of clinical knowledge,” Jan Bartels, Chief Executive Officer of InnoSer International explains. “This partnership underscores our shared desire to contribute innovation and efficiency to advance patient care, ensuring that together, we set a new standard for excellence in the biopharmaceutical contract research services industry.”

Hadil Es-Sbai, Chief Executive Officer of CR2O, comments: “We see the need to solve the persistent problem of the fragmented approach to R&D. We are therefore pleased that through our partnership with InnoSer, we can now offer our customers end-to-end, fully integrated, and validated drug development pathways. This partnership allows us to provide a streamlined approach, aligning all aspects of the development process”.

Looking ahead, InnoSer and CR2O are committed to driving innovation in the drug development sector. By combining their resources and expertise, the two companies aim to set a new standard for excellence, providing their clients with increased confidence across the development lifecycle by de-risking activities and reducing associated costs.